GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ionis Pharmaceuticals Inc (NAS:IONS) » Definitions » Shiller PE Ratio

IONS (Ionis Pharmaceuticals) Shiller PE Ratio : (As of Dec. 13, 2024)


View and export this data going back to 1991. Start your Free Trial

What is Ionis Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Ionis Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Ionis Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ionis Pharmaceuticals Shiller PE Ratio Chart

Ionis Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Ionis Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ionis Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Ionis Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ionis Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Ionis Pharmaceuticals's Shiller PE Ratio falls into.



Ionis Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Ionis Pharmaceuticals's E10 for the quarter that ended in Sep. 2024 is calculated as:

For example, Ionis Pharmaceuticals's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.95/133.0289*133.0289
=-0.950

Current CPI (Sep. 2024) = 133.0289.

Ionis Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201412 0.250 99.070 0.336
201503 -0.140 99.621 -0.187
201506 0.290 100.684 0.383
201509 -0.300 100.392 -0.398
201512 -0.590 99.792 -0.787
201603 -0.520 100.470 -0.689
201606 -0.470 101.688 -0.615
201609 0.060 101.861 0.078
201612 0.210 101.863 0.274
201703 0.070 102.862 0.091
201706 -0.020 103.349 -0.026
201709 -0.020 104.136 -0.026
201712 0.020 104.011 0.026
201803 -0.010 105.290 -0.013
201806 -0.290 106.317 -0.363
201809 -0.030 106.507 -0.037
201812 2.210 105.998 2.774
201903 0.620 107.251 0.769
201906 -0.010 108.070 -0.012
201909 0.180 108.329 0.221
201912 1.280 108.420 1.571
202003 -0.280 108.902 -0.342
202006 -0.180 108.767 -0.220
202009 -0.180 109.815 -0.218
202012 -2.440 109.897 -2.954
202103 -0.640 111.754 -0.762
202106 -0.570 114.631 -0.661
202109 -0.580 115.734 -0.667
202112 1.410 117.630 1.595
202203 -0.460 121.301 -0.504
202206 -0.740 125.017 -0.787
202209 -0.330 125.227 -0.351
202212 -0.370 125.222 -0.393
202303 -0.870 127.348 -0.909
202306 -0.600 128.729 -0.620
202309 -1.030 129.860 -1.055
202312 -0.060 129.419 -0.062
202403 -0.980 131.776 -0.989
202406 -0.450 132.554 -0.452
202409 -0.950 133.029 -0.950

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Ionis Pharmaceuticals  (NAS:IONS) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Ionis Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Ionis Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Ionis Pharmaceuticals Business Description

Traded in Other Exchanges
Address
2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
Executives
Joseph Loscalzo director
Eric Swayze officer: SVP, Research 2855 GAZELLE COURT, 2855 GAZELLE COURT, CARLSBAD CA 92010
Brett P Monia director, officer: Senior Vice President 2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
Richard S Geary officer: Senior Vice President 2855 GAZELLE COURT, 2855 GAZELLE COURT, CARLSBAD CA 92010
Allene M. Diaz director C/O ALLENA PHARMACEUTIALS, INC., ONEW NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA 02462
Joseph Iii Klein director C/O GENAISSANCE PHARMACEUTICALS INC, FIVE SCIENCE PARK, NEW HAVEN CT 06511
Spencer R Berthelsen director 2855 GAZELLE COURT, CARLSBAD CA 92010
Brian Birchler officer: EVP, Corp and Development Ops C/O IONIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT, CARLSBAD CA 92010
Joseph Baroldi officer: Chief Business Officer C/O IONIS PHARMACEUTICALS, INC., C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
C Frank Bennett officer: Vice President 2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
Elizabeth L Hougen officer: SVP, Finance and CFO 2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
Eugene Schneider officer: EVP, Chf Clinical Develop Offc C/O IONIS PHARMACEUTICALS, 2855 GAZELLE CT, CARLSBAD CA 92010
Onaiza Cadoret-manier officer: Chief Corp Dev and Cml Officer 2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
Patrick R. O'neil officer: SVP, Legal and General Counsel C/O IONIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT, CARLSBAD CA 92010
B Lynne Parshall director, officer: Executive Vice President, CFO 2855 GAZELLE COURT, CARLSBAD CA 92010

Ionis Pharmaceuticals Headlines